nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolterodine—Dementia—Methotrexate—esophageal cancer	0.000978	0.0488	CcSEcCtD
Tolterodine—Infection—Carboplatin—esophageal cancer	0.000884	0.044	CcSEcCtD
Tolterodine—Pain—Carboplatin—esophageal cancer	0.000761	0.0379	CcSEcCtD
Tolterodine—Memory impairment—Capecitabine—esophageal cancer	0.000687	0.0342	CcSEcCtD
Tolterodine—Gastrooesophageal reflux disease—Capecitabine—esophageal cancer	0.000597	0.0297	CcSEcCtD
Tolterodine—Anaphylactoid reaction—Cisplatin—esophageal cancer	0.000548	0.0273	CcSEcCtD
Tolterodine—Influenza like illness—Capecitabine—esophageal cancer	0.000523	0.0261	CcSEcCtD
Tolterodine—Dry eye—Capecitabine—esophageal cancer	0.000498	0.0248	CcSEcCtD
Tolterodine—Abnormal vision—Capecitabine—esophageal cancer	0.00047	0.0234	CcSEcCtD
Tolterodine—Urinary retention—Capecitabine—esophageal cancer	0.000372	0.0185	CcSEcCtD
Tolterodine—Dry skin—Capecitabine—esophageal cancer	0.000359	0.0179	CcSEcCtD
Tolterodine—Visual impairment—Cisplatin—esophageal cancer	0.000354	0.0176	CcSEcCtD
Tolterodine—Flushing—Cisplatin—esophageal cancer	0.000341	0.017	CcSEcCtD
Tolterodine—Bronchitis—Capecitabine—esophageal cancer	0.000325	0.0162	CcSEcCtD
Tolterodine—Dysuria—Capecitabine—esophageal cancer	0.000316	0.0158	CcSEcCtD
Tolterodine—Flatulence—Cisplatin—esophageal cancer	0.000315	0.0157	CcSEcCtD
Tolterodine—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000314	0.0157	CcSEcCtD
Tolterodine—Weight increased—Capecitabine—esophageal cancer	0.000308	0.0153	CcSEcCtD
Tolterodine—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.000301	0.015	CcSEcCtD
Tolterodine—Urinary tract infection—Capecitabine—esophageal cancer	0.000293	0.0146	CcSEcCtD
Tolterodine—Anxiety—Cisplatin—esophageal cancer	0.000271	0.0135	CcSEcCtD
Tolterodine—Oedema peripheral—Capecitabine—esophageal cancer	0.000267	0.0133	CcSEcCtD
Tolterodine—Anaphylactic shock—Cisplatin—esophageal cancer	0.000261	0.013	CcSEcCtD
Tolterodine—Oedema—Cisplatin—esophageal cancer	0.000261	0.013	CcSEcCtD
Tolterodine—Visual impairment—Capecitabine—esophageal cancer	0.000261	0.013	CcSEcCtD
Tolterodine—Infection—Cisplatin—esophageal cancer	0.000259	0.0129	CcSEcCtD
Tolterodine—Tachycardia—Cisplatin—esophageal cancer	0.000255	0.0127	CcSEcCtD
Tolterodine—Flushing—Capecitabine—esophageal cancer	0.000251	0.0125	CcSEcCtD
Tolterodine—CHRM3—Metabolism—PSME1—esophageal cancer	0.000242	0.000247	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—SLC52A3—esophageal cancer	0.000241	0.000246	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—BLVRB—esophageal cancer	0.000241	0.000246	CbGpPWpGaD
Tolterodine—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000238	0.0118	CcSEcCtD
Tolterodine—CYP2C19—Metabolism—CYP26A1—esophageal cancer	0.000237	0.000241	CbGpPWpGaD
Tolterodine—Dysuria—Methotrexate—esophageal cancer	0.000235	0.0117	CcSEcCtD
Tolterodine—CYP2D6—Metabolism—ADH1B—esophageal cancer	0.000234	0.000239	CbGpPWpGaD
Tolterodine—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000234	0.0117	CcSEcCtD
Tolterodine—Flatulence—Capecitabine—esophageal cancer	0.000232	0.0116	CcSEcCtD
Tolterodine—CYP2C9—Metabolism—ADH1B—esophageal cancer	0.000232	0.000237	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—XIAP—esophageal cancer	0.000231	0.000236	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—XIAP—esophageal cancer	0.000231	0.000235	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—ALOX15—esophageal cancer	0.00023	0.000235	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—XIAP—esophageal cancer	0.000228	0.000233	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—TGFBR2—esophageal cancer	0.000226	0.000231	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—TYMP—esophageal cancer	0.000224	0.000228	CbGpPWpGaD
Tolterodine—Pain—Cisplatin—esophageal cancer	0.000223	0.0111	CcSEcCtD
Tolterodine—CYP2C9—Metabolism—TYMP—esophageal cancer	0.000222	0.000226	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—GSTO1—esophageal cancer	0.00022	0.000224	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—TPI1—esophageal cancer	0.00022	0.000224	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CTNNA1—esophageal cancer	0.000219	0.000223	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CTNNA1—esophageal cancer	0.000218	0.000222	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—CYP26A1—esophageal cancer	0.000218	0.000222	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CXCL2—esophageal cancer	0.000217	0.000222	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CXCL2—esophageal cancer	0.000217	0.000221	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—TGFBR2—esophageal cancer	0.000217	0.000221	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CTNNA1—esophageal cancer	0.000216	0.00022	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—CYP26A1—esophageal cancer	0.000216	0.00022	CbGpPWpGaD
Tolterodine—Feeling abnormal—Cisplatin—esophageal cancer	0.000215	0.0107	CcSEcCtD
Tolterodine—CHRM2—Signaling Pathways—CXCL2—esophageal cancer	0.000215	0.000219	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—SMAD4—esophageal cancer	0.000214	0.000218	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—ALOX15—esophageal cancer	0.000212	0.000216	CbGpPWpGaD
Tolterodine—Vertigo—Capecitabine—esophageal cancer	0.000212	0.0106	CcSEcCtD
Tolterodine—CYP2C19—Metabolism—ALDOB—esophageal cancer	0.000211	0.000215	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—ALOX15—esophageal cancer	0.00021	0.000214	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—CYP1B1—esophageal cancer	0.000209	0.000213	CbGpPWpGaD
Tolterodine—Palpitations—Capecitabine—esophageal cancer	0.000208	0.0104	CcSEcCtD
Tolterodine—CYP3A4—Metabolism—SLC10A2—esophageal cancer	0.000205	0.000209	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CA1—esophageal cancer	0.000205	0.000209	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—SMAD4—esophageal cancer	0.000205	0.000209	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—PSME1—esophageal cancer	0.000203	0.000207	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—PSME2—esophageal cancer	0.000203	0.000207	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—GAPDH—esophageal cancer	0.000203	0.000207	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—PSME2—esophageal cancer	0.000202	0.000207	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—PSME1—esophageal cancer	0.000202	0.000207	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—GSTO1—esophageal cancer	0.000202	0.000206	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—TPI1—esophageal cancer	0.000202	0.000206	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—ANXA1—esophageal cancer	0.000202	0.000206	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—ANXA1—esophageal cancer	0.000202	0.000206	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—CRABP1—esophageal cancer	0.000201	0.000205	CbGpPWpGaD
Tolterodine—Chest pain—Capecitabine—esophageal cancer	0.000201	0.01	CcSEcCtD
Tolterodine—Arthralgia—Capecitabine—esophageal cancer	0.000201	0.01	CcSEcCtD
Tolterodine—CHRM2—Signaling Pathways—PSME2—esophageal cancer	0.000201	0.000205	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—PSME1—esophageal cancer	0.000201	0.000205	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—TPI1—esophageal cancer	0.0002	0.000205	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—GSTO1—esophageal cancer	0.0002	0.000205	CbGpPWpGaD
Tolterodine—Anxiety—Capecitabine—esophageal cancer	0.0002	0.00996	CcSEcCtD
Tolterodine—CHRM2—Signaling Pathways—ANXA1—esophageal cancer	0.0002	0.000204	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—SST—esophageal cancer	0.000197	0.000201	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—CYP19A1—esophageal cancer	0.000196	0.0002	CbGpPWpGaD
Tolterodine—Dry mouth—Capecitabine—esophageal cancer	0.000196	0.00978	CcSEcCtD
Tolterodine—CHRM3—Signaling Pathways—SST—esophageal cancer	0.000196	0.0002	CbGpPWpGaD
Tolterodine—Visual impairment—Methotrexate—esophageal cancer	0.000194	0.00968	CcSEcCtD
Tolterodine—CHRM2—Signaling Pathways—SST—esophageal cancer	0.000194	0.000198	CbGpPWpGaD
Tolterodine—Confusional state—Capecitabine—esophageal cancer	0.000194	0.00967	CcSEcCtD
Tolterodine—CYP2D6—Metabolism—ALDOB—esophageal cancer	0.000194	0.000198	CbGpPWpGaD
Tolterodine—Oedema—Capecitabine—esophageal cancer	0.000192	0.00959	CcSEcCtD
Tolterodine—CYP2C9—Metabolism—ALDOB—esophageal cancer	0.000192	0.000196	CbGpPWpGaD
Tolterodine—Hypersensitivity—Cisplatin—esophageal cancer	0.000192	0.00958	CcSEcCtD
Tolterodine—CHRM1—Signaling Pathways—GHRL—esophageal cancer	0.000192	0.000196	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—NOTCH3—esophageal cancer	0.000192	0.000196	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—GNG7—esophageal cancer	0.000191	0.000195	CbGpPWpGaD
Tolterodine—Infection—Capecitabine—esophageal cancer	0.000191	0.00952	CcSEcCtD
Tolterodine—CHRM3—Signaling Pathways—NOTCH3—esophageal cancer	0.000191	0.000195	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—GHRL—esophageal cancer	0.000191	0.000195	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—NOTCH3—esophageal cancer	0.000189	0.000193	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—GHRL—esophageal cancer	0.000189	0.000193	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—FBXW7—esophageal cancer	0.000189	0.000192	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—FBXW7—esophageal cancer	0.000188	0.000192	CbGpPWpGaD
Tolterodine—Tachycardia—Capecitabine—esophageal cancer	0.000188	0.00936	CcSEcCtD
Tolterodine—CYP3A4—Metabolism—CA2—esophageal cancer	0.000188	0.000192	CbGpPWpGaD
Tolterodine—Asthenia—Cisplatin—esophageal cancer	0.000187	0.00933	CcSEcCtD
Tolterodine—CYP2D6—Metabolism—GAPDH—esophageal cancer	0.000187	0.00019	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—FBXW7—esophageal cancer	0.000186	0.00019	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—GAPDH—esophageal cancer	0.000185	0.000189	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—CRABP1—esophageal cancer	0.000185	0.000189	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—CRABP1—esophageal cancer	0.000183	0.000187	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—HMOX1—esophageal cancer	0.000179	0.000183	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—ALDH2—esophageal cancer	0.000179	0.000183	CbGpPWpGaD
Tolterodine—Diarrhoea—Cisplatin—esophageal cancer	0.000179	0.0089	CcSEcCtD
Tolterodine—CYP2D6—Metabolism—GNG7—esophageal cancer	0.000176	0.00018	CbGpPWpGaD
Tolterodine—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000175	0.00873	CcSEcCtD
Tolterodine—CHRM4—Signaling Pathways—HIF1A—esophageal cancer	0.000175	0.000179	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PLCE1—esophageal cancer	0.000174	0.000178	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—ADH7—esophageal cancer	0.000174	0.000178	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—GNG7—esophageal cancer	0.000174	0.000178	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—ABCB1—esophageal cancer	0.000172	0.000176	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—NOTCH2—esophageal cancer	0.000172	0.000175	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—NOTCH2—esophageal cancer	0.000171	0.000175	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—GSTT1—esophageal cancer	0.00017	0.000174	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—NOTCH2—esophageal cancer	0.00017	0.000173	CbGpPWpGaD
Tolterodine—Dyspepsia—Capecitabine—esophageal cancer	0.000169	0.00844	CcSEcCtD
Tolterodine—CYP2C19—Metabolism—CYP2A6—esophageal cancer	0.000169	0.000172	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	0.000168	0.000171	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—HIF1A—esophageal cancer	0.000168	0.000171	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—KDR—esophageal cancer	0.000168	0.000171	CbGpPWpGaD
Tolterodine—Fatigue—Capecitabine—esophageal cancer	0.000166	0.00826	CcSEcCtD
Tolterodine—CYP2D6—Metabolism—ALDH2—esophageal cancer	0.000165	0.000168	CbGpPWpGaD
Tolterodine—Constipation—Capecitabine—esophageal cancer	0.000164	0.0082	CcSEcCtD
Tolterodine—Pain—Capecitabine—esophageal cancer	0.000164	0.0082	CcSEcCtD
Tolterodine—CYP2C9—Metabolism—ALDH2—esophageal cancer	0.000163	0.000167	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—KDR—esophageal cancer	0.00016	0.000164	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PTGS1—esophageal cancer	0.00016	0.000163	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—ENO1—esophageal cancer	0.00016	0.000163	CbGpPWpGaD
Tolterodine—Feeling abnormal—Capecitabine—esophageal cancer	0.000158	0.0079	CcSEcCtD
Tolterodine—CHRM4—Signaling Pathways—NOTCH1—esophageal cancer	0.000158	0.000161	CbGpPWpGaD
Tolterodine—Vertigo—Methotrexate—esophageal cancer	0.000158	0.00786	CcSEcCtD
Tolterodine—CYP2C19—Metabolism—PSME2—esophageal cancer	0.000157	0.000161	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PSME1—esophageal cancer	0.000157	0.000161	CbGpPWpGaD
Tolterodine—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000157	0.00784	CcSEcCtD
Tolterodine—CYP2D6—Metabolism—GSTT1—esophageal cancer	0.000157	0.00016	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—GSTT1—esophageal cancer	0.000155	0.000159	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—CYP2A6—esophageal cancer	0.000155	0.000158	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—CYP2A6—esophageal cancer	0.000154	0.000157	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	0.000153	0.000156	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—ADH1B—esophageal cancer	0.000153	0.000156	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—TGFBR2—esophageal cancer	0.000152	0.000156	CbGpPWpGaD
Tolterodine—Abdominal pain—Capecitabine—esophageal cancer	0.000152	0.00758	CcSEcCtD
Tolterodine—CHRM3—Signaling Pathways—TGFBR2—esophageal cancer	0.000152	0.000155	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—NOTCH1—esophageal cancer	0.000151	0.000154	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—TGFBR2—esophageal cancer	0.000151	0.000154	CbGpPWpGaD
Tolterodine—Chest pain—Methotrexate—esophageal cancer	0.000149	0.00744	CcSEcCtD
Tolterodine—Arthralgia—Methotrexate—esophageal cancer	0.000149	0.00744	CcSEcCtD
Tolterodine—CYP2D6—Metabolism—ENO1—esophageal cancer	0.000147	0.00015	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PTGS1—esophageal cancer	0.000147	0.00015	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—TYMP—esophageal cancer	0.000146	0.000149	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—ENO1—esophageal cancer	0.000146	0.000149	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PTGS1—esophageal cancer	0.000146	0.000149	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PSME1—esophageal cancer	0.000145	0.000148	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PSME2—esophageal cancer	0.000145	0.000148	CbGpPWpGaD
Tolterodine—Confusional state—Methotrexate—esophageal cancer	0.000144	0.00719	CcSEcCtD
Tolterodine—CHRM1—Signaling Pathways—SMAD4—esophageal cancer	0.000144	0.000147	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—SMAD4—esophageal cancer	0.000144	0.000147	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PSME1—esophageal cancer	0.000144	0.000146	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PSME2—esophageal cancer	0.000144	0.000146	CbGpPWpGaD
Tolterodine—Anaphylactic shock—Methotrexate—esophageal cancer	0.000143	0.00714	CcSEcCtD
Tolterodine—CHRM4—Signaling Pathways—CREBBP—esophageal cancer	0.000143	0.000146	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—SMAD4—esophageal cancer	0.000142	0.000145	CbGpPWpGaD
Tolterodine—Infection—Methotrexate—esophageal cancer	0.000142	0.00709	CcSEcCtD
Tolterodine—CYP3A4—Metabolism—CYP26A1—esophageal cancer	0.000142	0.000145	CbGpPWpGaD
Tolterodine—Hypersensitivity—Capecitabine—esophageal cancer	0.000142	0.00706	CcSEcCtD
Tolterodine—CHRM4—Signaling by GPCR—EGFR—esophageal cancer	0.000141	0.000143	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—ALOX15—esophageal cancer	0.000139	0.000141	CbGpPWpGaD
Tolterodine—Asthenia—Capecitabine—esophageal cancer	0.000138	0.00688	CcSEcCtD
Tolterodine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	0.000137	0.00014	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—CREBBP—esophageal cancer	0.000137	0.00014	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—CYP1B1—esophageal cancer	0.000136	0.000139	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—EGFR—esophageal cancer	0.000135	0.000137	CbGpPWpGaD
Tolterodine—CHRM4—GPCR downstream signaling—PIK3CA—esophageal cancer	0.000134	0.000137	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—TPI1—esophageal cancer	0.000132	0.000135	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—GSTO1—esophageal cancer	0.000132	0.000135	CbGpPWpGaD
Tolterodine—Diarrhoea—Capecitabine—esophageal cancer	0.000132	0.00656	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.00013	0.0065	CcSEcCtD
Tolterodine—CHRM5—GPCR downstream signaling—PIK3CA—esophageal cancer	0.000129	0.000131	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—NOS3—esophageal cancer	0.000128	0.000131	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—CYP19A1—esophageal cancer	0.000128	0.00013	CbGpPWpGaD
Tolterodine—Somnolence—Methotrexate—esophageal cancer	0.000127	0.00634	CcSEcCtD
Tolterodine—Dizziness—Capecitabine—esophageal cancer	0.000127	0.00634	CcSEcCtD
Tolterodine—CYP3A4—Metabolism—ALDOB—esophageal cancer	0.000127	0.000129	CbGpPWpGaD
Tolterodine—Dyspepsia—Methotrexate—esophageal cancer	0.000126	0.00628	CcSEcCtD
Tolterodine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	0.000125	0.000128	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—CYP1B1—esophageal cancer	0.000125	0.000128	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—CYP1B1—esophageal cancer	0.000124	0.000126	CbGpPWpGaD
Tolterodine—Fatigue—Methotrexate—esophageal cancer	0.000123	0.00615	CcSEcCtD
Tolterodine—CHRM5—Signaling Pathways—NOS3—esophageal cancer	0.000123	0.000125	CbGpPWpGaD
Tolterodine—Pain—Methotrexate—esophageal cancer	0.000122	0.0061	CcSEcCtD
Tolterodine—CYP3A4—Metabolism—GAPDH—esophageal cancer	0.000122	0.000125	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—PIK3CA—esophageal cancer	0.000122	0.000125	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CRABP1—esophageal cancer	0.000121	0.000123	CbGpPWpGaD
Tolterodine—Headache—Capecitabine—esophageal cancer	0.00012	0.006	CcSEcCtD
Tolterodine—CHRM4—Signaling Pathways—ERBB2—esophageal cancer	0.00012	0.000122	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—HIF1A—esophageal cancer	0.000118	0.000121	CbGpPWpGaD
Tolterodine—Feeling abnormal—Methotrexate—esophageal cancer	0.000118	0.00588	CcSEcCtD
Tolterodine—CHRM3—Signaling Pathways—HIF1A—esophageal cancer	0.000118	0.00012	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—CYP19A1—esophageal cancer	0.000117	0.00012	CbGpPWpGaD
Tolterodine—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000117	0.00584	CcSEcCtD
Tolterodine—CHRM5—Signaling by GPCR—PIK3CA—esophageal cancer	0.000117	0.000119	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—HIF1A—esophageal cancer	0.000117	0.000119	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—HMOX1—esophageal cancer	0.000117	0.000119	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—CYP19A1—esophageal cancer	0.000116	0.000119	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—GNG7—esophageal cancer	0.000115	0.000117	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—CREBBP—esophageal cancer	0.000115	0.000117	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—ERBB2—esophageal cancer	0.000115	0.000117	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	0.000114	0.000117	CbGpPWpGaD
Tolterodine—Abdominal pain—Methotrexate—esophageal cancer	0.000113	0.00564	CcSEcCtD
Tolterodine—CHRM1—Signaling Pathways—KDR—esophageal cancer	0.000113	0.000115	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—KDR—esophageal cancer	0.000113	0.000115	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—ABCB1—esophageal cancer	0.000112	0.000114	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—KDR—esophageal cancer	0.000111	0.000114	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—ALDH2—esophageal cancer	0.000108	0.00011	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—HMOX1—esophageal cancer	0.000107	0.000109	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—NOTCH1—esophageal cancer	0.000106	0.000109	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—HMOX1—esophageal cancer	0.000106	0.000108	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—NOTCH1—esophageal cancer	0.000106	0.000108	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—CCND1—esophageal cancer	0.000106	0.000108	CbGpPWpGaD
Tolterodine—Hypersensitivity—Methotrexate—esophageal cancer	0.000105	0.00526	CcSEcCtD
Tolterodine—CHRM2—Signaling Pathways—NOTCH1—esophageal cancer	0.000105	0.000107	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	0.000104	0.000106	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—NOS3—esophageal cancer	0.000103	0.000105	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—ABCB1—esophageal cancer	0.000103	0.000105	CbGpPWpGaD
Tolterodine—Asthenia—Methotrexate—esophageal cancer	0.000103	0.00512	CcSEcCtD
Tolterodine—CYP3A4—Metabolism—GSTT1—esophageal cancer	0.000103	0.000105	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—CDKN1A—esophageal cancer	0.000102	0.000105	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—ABCB1—esophageal cancer	0.000102	0.000104	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—CCND1—esophageal cancer	0.000101	0.000103	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CYP2A6—esophageal cancer	0.000101	0.000103	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—CDKN1A—esophageal cancer	9.81e-05	0.0001	CbGpPWpGaD
Tolterodine—Diarrhoea—Methotrexate—esophageal cancer	9.8e-05	0.00488	CcSEcCtD
Tolterodine—CHRM4—Signaling Pathways—EP300—esophageal cancer	9.74e-05	9.94e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CREBBP—esophageal cancer	9.65e-05	9.84e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CREBBP—esophageal cancer	9.62e-05	9.81e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PTGS1—esophageal cancer	9.61e-05	9.8e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—ENO1—esophageal cancer	9.61e-05	9.8e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CREBBP—esophageal cancer	9.52e-05	9.72e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—EGFR—esophageal cancer	9.48e-05	9.67e-05	CbGpPWpGaD
Tolterodine—Dizziness—Methotrexate—esophageal cancer	9.47e-05	0.00472	CcSEcCtD
Tolterodine—CYP3A4—Metabolism—PSME1—esophageal cancer	9.47e-05	9.66e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PSME2—esophageal cancer	9.47e-05	9.66e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—EGFR—esophageal cancer	9.45e-05	9.64e-05	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—PTGS2—esophageal cancer	9.42e-05	9.61e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—EGFR—esophageal cancer	9.36e-05	9.55e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—EP300—esophageal cancer	9.33e-05	9.52e-05	CbGpPWpGaD
Tolterodine—CHRM1—GPCR downstream signaling—PIK3CA—esophageal cancer	9.06e-05	9.25e-05	CbGpPWpGaD
Tolterodine—CHRM3—GPCR downstream signaling—PIK3CA—esophageal cancer	9.03e-05	9.22e-05	CbGpPWpGaD
Tolterodine—Headache—Methotrexate—esophageal cancer	8.97e-05	0.00447	CcSEcCtD
Tolterodine—CHRM2—GPCR downstream signaling—PIK3CA—esophageal cancer	8.94e-05	9.13e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—NOS3—esophageal cancer	8.64e-05	8.81e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—NOS3—esophageal cancer	8.61e-05	8.79e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—NOS3—esophageal cancer	8.53e-05	8.7e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—MYC—esophageal cancer	8.49e-05	8.67e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	8.46e-05	8.63e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—EGFR—esophageal cancer	8.31e-05	8.48e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—PIK3CA—esophageal cancer	8.23e-05	8.4e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—PIK3CA—esophageal cancer	8.2e-05	8.37e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CYP1B1—esophageal cancer	8.17e-05	8.34e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—MYC—esophageal cancer	8.13e-05	8.3e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—PIK3CA—esophageal cancer	8.12e-05	8.29e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—ERBB2—esophageal cancer	8.08e-05	8.24e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—ERBB2—esophageal cancer	8.05e-05	8.22e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—ERBB2—esophageal cancer	7.98e-05	8.14e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—EGFR—esophageal cancer	7.95e-05	8.12e-05	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—EP300—esophageal cancer	7.83e-05	7.99e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	7.71e-05	7.87e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CYP19A1—esophageal cancer	7.68e-05	7.84e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—CREBBP—esophageal cancer	7.48e-05	7.63e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—PIK3CA—esophageal cancer	7.21e-05	7.36e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CCND1—esophageal cancer	7.14e-05	7.28e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CCND1—esophageal cancer	7.12e-05	7.26e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CCND1—esophageal cancer	7.05e-05	7.19e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—HMOX1—esophageal cancer	7.01e-05	7.15e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—TP53—esophageal cancer	6.97e-05	7.12e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CDKN1A—esophageal cancer	6.91e-05	7.05e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—PIK3CA—esophageal cancer	6.9e-05	7.04e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CDKN1A—esophageal cancer	6.88e-05	7.02e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—CREBBP—esophageal cancer	6.88e-05	7.02e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—CREBBP—esophageal cancer	6.82e-05	6.96e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CDKN1A—esophageal cancer	6.82e-05	6.96e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—ABCB1—esophageal cancer	6.73e-05	6.86e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—NOS3—esophageal cancer	6.69e-05	6.83e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—TP53—esophageal cancer	6.68e-05	6.81e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—EP300—esophageal cancer	6.57e-05	6.7e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—EP300—esophageal cancer	6.55e-05	6.68e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—EP300—esophageal cancer	6.49e-05	6.62e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—NOS3—esophageal cancer	6.16e-05	6.28e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PTGS2—esophageal cancer	6.12e-05	6.25e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—NOS3—esophageal cancer	6.1e-05	6.23e-05	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—PIK3CA—esophageal cancer	5.79e-05	5.91e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—MYC—esophageal cancer	5.73e-05	5.84e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—MYC—esophageal cancer	5.71e-05	5.82e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—MYC—esophageal cancer	5.65e-05	5.77e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PTGS2—esophageal cancer	5.63e-05	5.75e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—EGFR—esophageal cancer	5.6e-05	5.71e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PTGS2—esophageal cancer	5.58e-05	5.7e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—EGFR—esophageal cancer	5.58e-05	5.7e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—EGFR—esophageal cancer	5.53e-05	5.64e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—EP300—esophageal cancer	5.09e-05	5.2e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—PIK3CA—esophageal cancer	4.86e-05	4.96e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—PIK3CA—esophageal cancer	4.84e-05	4.94e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—PIK3CA—esophageal cancer	4.8e-05	4.9e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—TP53—esophageal cancer	4.7e-05	4.8e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—TP53—esophageal cancer	4.69e-05	4.78e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—EP300—esophageal cancer	4.68e-05	4.78e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—EP300—esophageal cancer	4.64e-05	4.74e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—TP53—esophageal cancer	4.64e-05	4.74e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CREBBP—esophageal cancer	4.5e-05	4.59e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—NOS3—esophageal cancer	4.03e-05	4.11e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PIK3CA—esophageal cancer	3.77e-05	3.84e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PTGS2—esophageal cancer	3.68e-05	3.76e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PIK3CA—esophageal cancer	3.46e-05	3.54e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PIK3CA—esophageal cancer	3.43e-05	3.5e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—EP300—esophageal cancer	3.06e-05	3.12e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PIK3CA—esophageal cancer	2.27e-05	2.31e-05	CbGpPWpGaD
